source
- Hims & Hers pivots to branded GLP-1 drugs after striking deal with Eli LillyHims & Hers, which previously emphasized personalized care through compounded products, is changing its business model. The company is now focusing on established brand-name GLP-1 treatments rathe…
- Beam Therapeutics reports year-long reduction in sickle cell crises in phase 1/2 risto-cel studyBeam Therapeutics disclosed data from its phase 1/2 trial of risto-cel, a base-edited autologous cell therapy targeting the BCL11A gene in sickle cell disease. The trial enrolled 31 adults and ado…